PCSK9 has emerged in recent years as an important target in the management of atherosclerosis and has been targeted by monoclonal antibody drugs (evolocumab and alirocumab) [22••] and inclisiran [23], leading to substantial reductions in LDL-C. This evidence concerns the gene PCSK9 and atherosclerosis.